Combination of Antistaphylococcal β-Lactam With Standard Therapy Compared to Standard Therapy Alone for the Treatment of Methicillin-Resistant

DOOR MRSA bacteremia bloodstream infection methicillin-resistant Staphylococcus aureus

Journal

Open forum infectious diseases

ISSN: 2328-8957

Titre abrégé: Open Forum Infect Dis

Pays: United States

ID NLM: 101637045

Informations de publication

Date de publication:
May 2024

Historique:

received: 08 02 2024

medline: 3 5 2024

pubmed: 3 5 2024

entrez: 3 5 2024

Statut: epublish

Résumé

Desirability of outcome ranking (DOOR) is an emerging approach to clinical trial outcome measurement using an ordinal scale to incorporate efficacy and safety endpoints. We applied a previously validated DOOR endpoint to a cohort of CAMERA2 trial participants with methicillin-resistant Participants assigned combination therapy had a 54.5% (95% confidence interval [CI], 48.9%-60.1%; When considering both efficacy and safety, treatment of MRSAB with a combination of standard therapy and a β-lactam likely results in a worse clinical outcome than standard therapy. However, a small benefit of combination therapy cannot be excluded. Most likely the toxicity of combination therapy outweighed any benefit from faster clearance of bacteremia.

Sections du résumé

Background UNASSIGNED

Desirability of outcome ranking (DOOR) is an emerging approach to clinical trial outcome measurement using an ordinal scale to incorporate efficacy and safety endpoints.

Methods UNASSIGNED

We applied a previously validated DOOR endpoint to a cohort of CAMERA2 trial participants with methicillin-resistant

Results UNASSIGNED

Participants assigned combination therapy had a 54.5% (95% confidence interval [CI], 48.9%-60.1%;

Conclusions UNASSIGNED

When considering both efficacy and safety, treatment of MRSAB with a combination of standard therapy and a β-lactam likely results in a worse clinical outcome than standard therapy. However, a small benefit of combination therapy cannot be excluded. Most likely the toxicity of combination therapy outweighed any benefit from faster clearance of bacteremia.

Identifiants

DOI: 10.1093/ofid/ofae181 PMID: 38698894 PMC: PMC11065345

pubmed: 38698894

doi: 10.1093/ofid/ofae181

pii: ofae181

pmc: PMC11065345

doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofae181

Investigateurs

David C Lye (DC)

Dafna Yahav (D)

Archana Sud (A)

J Owen Robinson (JO)

Jane Nelson (J)

Sophia Archuleta (S)

Matthew A Roberts (MA)

Alan Cass (A)

David L Paterson (DL)

Hong Foo (H)

Mical Paul (M)

Stephen D Guy (SD)

Adrian R Tramontana (AR)

Genevieve B Walls (GB)

Stephen McBride (S)

Narin Bak (N)

Niladri Ghosh (N)

Benjamin A Rogers (BA)

Anna P Ralph (AP)

Jane Davies (J)

Patricia E Ferguson (PE)

Ravindra Dotel (R)

Genevieve L McKew (GL)

Timothy J Gray (TJ)

Natasha E Holmes (NE)

Simon Smith (S)

Morgyn S Warner (MS)

Shirin Kalimuddin (S)

Barnaby E Young (BE)

Naomi Runnegar (N)

David N Andresen (DN)

Nicholas A Anagnostou (NA)

Sandra A Johnson (SA)

Mark D Chatfield (MD)

Allen C Cheng (AC)

Vance G Fowler (VG)

Benjamin P Howden (BP)

Niamh Meagher (N)

David J Price (DJ)

Sebastiaan J van Hal (SJ)

Matthew V N O Sullivan (MVNO)

Informations de copyright

Déclaration de conflit d'intérêts

Potential conflicts of interest. All authors: No reported conflicts.